Efficacy and Safety Profile of Glucagon-Like Peptide-1 Receptor Agonist in Obese Type-2 Diabetes Patients from a Private Institution in Karachi

Overview

Journal Pak J Med Sci

Specialty General Medicine

Date 2023 Jul 26

PMID 37492314

Authors

Saeeda Fouzia Qasim

Tasnim Ahsan

Saima Ghaus

Paras Imran

Affiliations

Soon will be listed here.

Abstract

Objective: To assess the effectiveness of GLP-1RAs in managing obese T2DM patients.

Methods: This prospective cohort analysis was conducted at Medicell Institute of Diabetes, Karachi, Pakistan; from July 2019 to July 2021. A total of 97 obese individuals >16 years of age with T2DM and IGT were initially enrolled, and 81 patients who showed up for the follow-up were prescribed one of the three GLP-1RAs available in Pakistan.

Results: Out of 81 patients who showed up for the follow-up visit, 43 had received Liraglutide, 25 were taking Dulaglutide, and 13 had been prescribed IDegLira supplemented with oral hypoglycemic medications ± insulin. The mean age of the enrolled patients was 49.21(12.44) years, and there was female predominance (55.6%). Overall, there was a significant weight and BMI reduction among the patients treated with either of the GLP-1RAs (). Furthermore, significant glycemic control was observed in all three groups after the treatment. The Dulaglutide group demonstrated a more significant reduction of HbA1c compared to Liraglutide group, which showed more pronounced weight and BMI reduction. Nevertheless, this class of medications was well-tolerated, with nausea being the most often reported side effect.

Conclusion: GLP-1RAs showed favorable weight and HbA1c reduction among patients of all three treatment groups.

References

Dungan K, Tofe Povedano S, Forst T, Gonzalez J, Atisso C, Sealls W . Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014; 384(9951):1349-57. DOI: 10.1016/S0140-6736(14)60976-4. View

Jia X, Alam M, Ye Y, Bajaj M, Birnbaum Y . GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials. Cardiovasc Drugs Ther. 2018; 32(1):65-72. DOI: 10.1007/s10557-018-6773-2. View

Iqbal J, Wu H, Hu N, Zhou Y, Li L, Xiao F . Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials. Obes Rev. 2022; 23(6):e13435. DOI: 10.1111/obr.13435. View

Marso S, Baeres F, Bain S, Goldman B, Husain M, Nauck M . Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure. J Am Coll Cardiol. 2020; 75(10):1128-1141. DOI: 10.1016/j.jacc.2019.12.063. View

Gough S, Bode B, Woo V, Rodbard H, Linjawi S, Poulsen P . Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with.... Lancet Diabetes Endocrinol. 2014; 2(11):885-93. DOI: 10.1016/S2213-8587(14)70174-3. View

Mody R, Huang Q, Yu M, Zhao R, Patel H, Grabner M . Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States. Diabetes Obes Metab. 2018; 21(4):920-929. PMC: 6590811. DOI: 10.1111/dom.13603. View

MacIsaac R . Dulaglutide and Insulin: How Can the AWARD Studies Help Guide Clinical Practice?. Diabetes Ther. 2020; 11(8):1627-1638. PMC: 7376989. DOI: 10.1007/s13300-020-00863-5. View

Patel Chavez C, Cusi K, Kadiyala S . The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD. J Clin Endocrinol Metab. 2021; 107(1):29-38. PMC: 8684453. DOI: 10.1210/clinem/dgab578. View

Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan B . IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2021; 183:109119. PMC: 11057359. DOI: 10.1016/j.diabres.2021.109119. View

10.

Liu J, Guo S, Li H, Liu X . Effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on podocytes, inflammation, and oxidative stress in patients with diabetic nephropathy (DN). Pak J Med Sci. 2022; 38(5):1170-1174. PMC: 9247776. DOI: 10.12669/pjms.38.5.4719. View

11.

Hussain M, Babar M, Akhtar L, Hussain M . Neutrophil lymphocyte ratio (NLR): A well assessment tool of glycemic control in type 2 diabetic patients. Pak J Med Sci. 2018; 33(6):1366-1370. PMC: 5768826. DOI: 10.12669/pjms.336.12900. View

12.

Lorenz M, Lawson F, Owens D, Raccah D, Roy-Duval C, Lehmann A . Differential effects of glucagon-like peptide-1 receptor agonists on heart rate. Cardiovasc Diabetol. 2017; 16(1):6. PMC: 5237337. DOI: 10.1186/s12933-016-0490-6. View

13.

Chang K, Shao S, Kuo S, Yang C, Chen H, Chan Y . Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis. Cardiovasc Diabetol. 2020; 19(1):172. PMC: 7547475. DOI: 10.1186/s12933-020-01148-8. View

14.

Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M . Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. Int J Mol Sci. 2020; 21(6). PMC: 7139365. DOI: 10.3390/ijms21061907. View

15.

Rashid M, Jabeen S, Khoja A, Islam N . Efficacy of Liraglutide in clinical practice: Single centre experience. Pak J Med Sci. 2020; 36(3):432-437. PMC: 7150369. DOI: 10.12669/pjms.36.3.358. View

16.

Alexander J, Staab E, Wan W, Franco M, Knitter A, Skandari M . The Longer-Term Benefits and Harms of Glucagon-Like Peptide-1 Receptor Agonists: a Systematic Review and Meta-Analysis. J Gen Intern Med. 2021; 37(2):415-438. PMC: 8810987. DOI: 10.1007/s11606-021-07105-9. View

17.

Anirban M, Soumyabrata R, Debmalya S, Bhattacharjee K . Liraglutide - Indian Experience. Indian J Endocrinol Metab. 2019; 22(6):818-826. PMC: 6330852. DOI: 10.4103/ijem.IJEM_187_18. View

18.

Oe Y, Nomoto H, Nakamura A, Kuwabara S, Takahashi Y, Yasui A . Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study. J Diabetes Res. 2022; 2022:5603864. PMC: 8793345. DOI: 10.1155/2022/5603864. View

19.

Gerstein H, Colhoun H, Dagenais G, Diaz R, Lakshmanan M, Pais P . Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab. 2017; 20(1):42-49. DOI: 10.1111/dom.13028. View

20.

Linjawi S, Bode B, Chaykin L, Courreges J, Handelsman Y, Lehmann L . The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial. Diabetes Ther. 2016; 8(1):101-114. PMC: 5306117. DOI: 10.1007/s13300-016-0218-3. View